Lipid management - Who to screen? Who to treat?

Geriatrics and Aging

Volumn 8, Issue 10, 2005, Pages 21-28

  Fitchett, David ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Cardiovascular disease; Cholesterol; Lipid management; Statin

Indexed keywords

ATORVASTATIN; CERIVASTATIN; CHOLESTEROL; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN; SIMVASTATIN;

AGED; ARTICLE; BLOOD PRESSURE; CANCER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISABILITY; DRUG MECHANISM; DYSLIPIDEMIA; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; ISCHEMIC HEART DISEASE; LIVER DYSFUNCTION; MYOSITIS; PERIPHERAL VASCULAR DISEASE; PREDICTION; RHABDOMYOLYSIS; RISK FACTOR; SCREENING TEST; STROKE; TREATMENT PLANNING; VASCULAR DISEASE;

EID: 29544438130     PISSN: 14888408     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Cowell SJ, Newby DE, Prescott RJ, et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 2005;352:2389-97.
2. Rea TD, Breitner JC, Psaty BM, et al. Statin use and the risk of incident dementia: the cardiovascular health study. Arch Neurol 2005;62:1047-51.
3. Node K, Fujita M, Kitakaze M, et al. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 2003;108:839-43.
4. Agarwal R, Curley TM. The role of statins in chronic kidney disease. Am J Med Sci 2005;330:69-81.
5. Kronmal RA, Cain KC, Ye A, et al. Total serum cholesterol levels and mortality risk as a function of age; a report based on the Framingham data. Arch Int Med 1993;153:1065-73.
6. Houterman S, Vershuren WM, Hofman A, et al. Serum cholesterol is a risk factor for myocardial infarction in elderly men and women: the Rotterdam study. J Intern Med 1999;246:33.
7. Frost PH, Davis BR, Burlando AJ, et al. Serum lipids and the incidence of coronary heart disease. Circulation 1996;94:2388.
8. Abrams J, Vela BS, Coultas DB, et al. Coronary risk factors and their modification: lipids, smoking, hypertension, oestrogen, and the elderly. Curr Probl Cardiol 1995;20:610.
9. Ettinger WH, Wahl PW, Kuller LH, et al. Lipoprotein lipids in older people: results from the cardiovascular health study. Circulation 1992;86:858-69.
10. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease; a meta-analysis of randomized controlled trials. JAMA 1999;282:2340-6.
11. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4,444 patients with coronary heart disease. Lancet 1994;344:1383-9.
12. Sacks FM, Tonkin AM, Shepherd J, et al. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors. Circulation 2000;102:1893-900.
13. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.
14. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. New Eng J Med 1995;333:1301-7.
15. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
16. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.
17. Heart Protection Collaboration Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo controlled trial. Lancet 2002;360:7-22.
18. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623-30.
19. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96.
20. Briel M, Studer M, Glass TR, et al. Effects of statins on stroke presvention in patients with and without coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med 2004;117:596-606.
21. Adult Treatment Panel III. Executive summary of the third report of the national cholesterol education program (NCEP). JAMA 2001;285:2486-97.
22. Ko D, Mamdani M, Alter D. Lipid lowering therapy with statins in high-risk elderly patients: the treatment risk paradox. JAMA 2004;291:1864-70.
23. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002;288:462-7.
24. Benner JS, Glynn RJ, Mogun H, et al. Long term persistence in use of statin therapy in elderly patients. JAMA 2002;288:461.
25. Genest J, Frohlich J, Fodor G, et al. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. CMAJ 2003;169:921-4.
26. Shepherd J. A prospective study of pravastatin in the elderly at risk: new hope for older persons. Am J Geriatr Cardiol 2004;13(3 Suppl 1):S17-24.